Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TroVax plus pemetrexed/cisplatin in malignant pleural mesothelioma
2010-023230-22Phase 2Completed
- Sponsor
- Velindre University NHS Trust
- Start
- Mar 2011
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of MVA-5T4 in pleural mesothelioma, sponsored by Velindre University NHS Trust. Primary endpoint: Cellular immune response to 5T4 and MVA antigens. Started Mar 2011; status: completed.
02
Drugs
MVA-5T4
03
Conditions
pleural mesothelioma
Beyond the preview
Go deeper on 2010-023230-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023230-22.